Aprea Therapeutics completes 1-for-20 reverse stock split to regain Nasdaq compliance

Aprea Therapeutics, Inc.

Reverse stock split effective 5:00 pm ET on Feb 10, 2023; stock trades split-adjusted from Feb 13, 2023 under symbol APRE.
Outstanding shares reduced from ~53,631,405 to ~2,681,570; authorized shares and par value unchanged.
New CUSIP number 03836J201; fractional shares aggregated and sold, with cash payments to holders.
Split intended to increase per-share price to meet Nasdaq continued listing requirements.
Proportionate adjustments made to equity awards, option exercise prices, and shares available under plans.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Aprea Therapeutics, Inc.: Amended Certificate of Incorporation to effect a one-for-20 reverse stock split (effective 2023-02-10).

Change: charter amendment
Effective: 2023-02-10

Exact text from the filing

the Company filed an amendment to its Certificate of Incorporation (the ‘Amendment”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, with an effective time of 5:00 p.m. on February 10, 2023.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-018997

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.